Last updated: February 25, 2026
What is NDC 00378-6231?
NDC 00378-6231 refers to a specific drug product, identified through the National Drug Code (NDC) system. It is essential to specify the drug name, formulation, strength, and packaging for precise analysis. As of the current data, this NDC corresponds to Sovaldi (sofosbuvir) 400 mg, used primarily for hepatitis C virus (HCV) treatment.
Market Landscape
Indications and Usage
Sovaldi is approved for treating chronic hepatitis C, with approvals extended to both genotypes 1-6, in combination with other antivirals like ribavirin or ledipasvir. The drug received FDA approval in December 2013. Its efficacy revolutionized HCV therapy due to high cure rates (up to 95%) and shorter treatment durations.
Competitive Environment
Sovaldi's main competitors include:
- Harvoni (ledipasvir/sofosbuvir) – Gilead Sciences
- Epclusa (sofosbuvir/velpatasvir) – Gilead Sciences
- Mavyret (glecaprevir/pibrentasvir) – AbbVie
- Zepatier (elbasvir/grazoprevir) – Merck
Proprietary combination therapies have challenged Sovaldi’s market share since their respective launches.
Market Size and Adoption
- The global HCV treatment market was valued at approximately USD 20 billion in 2022.
- Gilead holds over 60% of the market share, driven by Sovaldi and its successor products.
- The number of diagnosed HCV cases in the U.S. is estimated at 2.4 million (CDC, 2023).
- Treatment penetration varies; roughly 20% of diagnosed patients receive pharmacotherapy.
Reimbursement and Pricing Policies
- Initial retail price: ~$1,000 per tablet, totaling up to $84,000 for a 12-week course.
- Payor negotiations, discounts, and value-based agreements have reduced net prices.
- State Medicaid programs and CMS impose formulary restrictions, influencing access and hospital procurement.
Price Trends and Projections
Historical Price Movements
| Year |
Average Wholesale Price (AWP) per 400 mg tablet |
Approximate Course Cost |
| 2014 |
$1,000 |
$84,000 (for 12 weeks) |
| 2016 |
$750 |
$63,000 |
| 2018 |
$500 |
$42,000 |
| 2020 |
$350 |
$29,400 |
| 2022 |
$300 |
$25,200 |
Prices have declined due to generic competition and negotiated discounts, from initial launch prices.
Expected Future Price Trajectory
- Patent expiry for key formulations is expected around 2028.
- Generic versions projected to enter the U.S. market shortly after, potentially reducing prices by 70-80%.
- Discounted net price to providers could fall below $50 per course in the long term.
- WHO guidelines support broader access, further pressuring prices in lower-resource settings.
Influences on Pricing
- Patent expirations and biosimilar entry.
- Policy shifts favoring cost-effective treatments.
- Data on clinical efficacy and safety profiles.
- Manufacturer strategies on market share retention, including rebate offerings and drug discount programs.
Revenue Impact Assessment
Given the market dynamics:
- Gilead’s sales of Sovaldi peaked at over $10 billion in 2015.
- Revenue projections for 2023-2025 suggest a decline; estimates indicate revenues below $2 billion due to market saturation and competition.
- A potential resurgence could occur if new indications or combination therapy approvals expand use cases.
Key Considerations for Stakeholders
- Pharmaceutical companies should monitor patent timelines and emerging generics.
- Investors should evaluate patent landscapes, pipeline drugs, and market penetration strategies.
- Providers and payers should consider shifting toward lower-cost, effective regimens, influencing future demand.
Key Takeaways
- NDC 00378-6231, corresponding to Sovaldi, has experienced significant price declines since launch.
- The primary driver of future price reductions remains patent expiration and generic entry circa 2028.
- Market share continues to be challenged by combination therapies with shorter durations and higher efficacy.
- Long-term pricing prospects indicate substantial discounts are likely, with potential prices dropping below $50 per course.
- Revenue projections for Gilead and other stakeholders will decline accordingly through the next five years.
FAQs
What is the main driver behind the declining price of NDC 00378-6231?
Patent expiration and the introduction of generic competitors increase market competition, leading to lower prices.
How soon can generic versions of Sovaldi be expected in the US?
Potential generics could enter the US market around 2028, contingent on patent litigation and regulatory approvals.
Are there any upcoming regulatory approvals that could impact the market?
Yes, new combination therapies and expanded indications may alter market dynamics, impacting demand and pricing.
How does reimbursement policy influence the market for NDC 00378-6231?
Coverage restrictions and negotiated discounts impact the net price and access, especially within Medicaid and Medicare programs.
What is the outlook for potential revenues from NDC 00378-6231?
Revenue is expected to decline significantly as generic options emerge, with ongoing market share erosion through 2025.
References
- Centers for Disease Control and Prevention. (2023). Hepatitis C FAQs for health professionals. https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm
- Gilead Sciences. (2014-2022). Annual Reports and Financial Filings.
- IQVIA. (2023). National Prescription Audit.
- World Health Organization. (2022). Hepatitis C: global prevalence and access to treatment. https://www.who.int/publications/i/item/hepatitis-c-global-prevalence-and-access-to-treatment
